Clinical trials with the use of topically applied liposomal formulation with bacteriophage T4 CPD damage removal enzyme – T4 endonuclease V resulted in lowered actinic keratoses and basal-cell carcinoma incidence in XP-patients [181,182]. This evidence concerns the gene ENDOV and xeroderma pigmentosum.